The
conference will have talks by leading scientists and doctors from
around the world and feature new research papers on the uses of GcMAF
to restore the body’s immune system to full strength to fight
diseases, autism and cancer.
St
Peter Port, Guernsey (February 26, 2013) -- The world's first
GcMAF
conference will be held on the 19th, 20th and 21st of April in the
attractive woodland Conference Centre at the Holiday Inn Frankfurt,
Germany. Sponsored by Immuno Biotech Ltd, the conference will have
talks by leading scientists and doctors from around the world and
feature new research papers on the uses of GcMAF to restore the
body's immune system to full strength to fight diseases, autism
and cancer.
David
Noakes, Immuno Biotech's CEO, said, "When research scientists
and doctors meet to add together their individual results into one
whole, the science takes a great step forward. It's a pooling of the
latest discoveries. We expect to come up with a definitive list of
synergistic treatments which will allow doctors to treat stage 3 and
some stage 4 cancers with the same 80% success that they achieve with
GcMAF alone on stage 2 cancers.
"At
the moment GcMAF eradicates autism in 15% of cases. By identifying
the best complimentary treatments we hope to take that up to 40%.
Amongst others, we hope to take ME/CFS from 30 to 50% success. The
workshops will encourage informal networking and new ideas. We have a
packed programme of talks by leading GcMAF researchers, doctors
reporting on their success at eradicating cancer, autism and ME/CFS
with GcMAF and, as a result, registrations are already flooding in."
Registration
is open now for doctors and research scientists at
http://gcmafconference.org
and, from March 20th, registration opens for members of the public
and patients wishing to learn more about GcMAF.
Immuno
Biotech extracts and isolates GcMAF molecules from healthy human
blood. As part of the process of tests and assays to ensure its GcMAF
is active, it has been conducting laboratory research into the
methods by which GcMAF destroys cancers cells, and is publishing its
first three research papers at international conferences on cancer,
immunology
and autism. Currently there are over 60 research papers on GcMAF by
142 eminent scientists with new peer-reviewed papers being added at
an increasing rate from university teams and doctors from dozens of
countries.
The
quality of Immuno Biotech's GcMAF has made it the World's leading
supplier and the provider of choice for doctors and scientists with
the company being cited in eleven research papers to date. Many of
the independent research papers on GcMAF are listed on its website
http://www.gcmaf.eu.
Background
GcMAF
is a vital part of the human immune system, which doesn't work
without it. However, many diseases including cancer attempt to
prevent production of the body's own GcMAF and, if successful, that
prevents the immune system from fighting them, resulting in the
diseases growing unchecked and becoming chronic.
Immuno
Biotech extracts GcMAF molecules from healthy blood. A weekly
injection of a tiny clear drop restores the level of GcMAF in the
blood to normal, effectively one millionth of a blood transfusion.
That enables the body's own immune system to fight the disease, with
the only occasional side effects being mild, cold-like symptoms as
the immune system starts to function normally. The time it takes for
the body to fight the infection and return to being able to produce
normal levels of its own GcMAF depends on the severity of the
infection or cancer. An eight week course costs €660 including
shipping so a typical 24 week course costs under €2000 - a fraction
of the cost of conventional treatments. Immuno Biotech has supplied
4,000 patients through 300 doctors in 30 nations.
Immuno
Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Ph: 0044 7781
411737, Website: http://www.gcmaf.eu
and click "contact" at the top to email.
